Back to Report Store Home

The Future of Generic Drugs and Strategies for Commercial Success

  • Published: Sep-2016
  • Report Code: GBI074CBR
  • Report Format: pdf

Description

List of Tables

Table 1: Generic Drugs by Type 9

Table 2: Generic Drug Entry Strategies 11

Table 3: Branded Drugs for which Authorized Generics Were Launched in US in 2015 38

Table 4: Selection of Branded Drugs for which First-Time Generics Have Been Launched in the US in 2015 39

Table 5: Super Generics Approved in the US, 2010–2014 40

Table 6: Super Generics Under Development in the US, 2016 41

Table 7: Teva, SWOT Analysis 58

Table 8: Sandoz, SWOT Analysis 59

Table 9: Mylan, SWOT Analysis 60

Table 10: Sun Pharma, SWOT Analysis 61

Table 11: Aspen, SWOT Analysis 62

Table 12: Hospira, SWOT Analysis 63

Table 13: Fresenius Kabi, SWOT Analysis 64

Table 14: Lupin, SWOT Analysis 65

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$2995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$5990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$8985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards